← All trials
NCT04590820
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2020
- Primary completion
- Jan 31, 2023
- Completion date
- Jan 31, 2025
- First posted
- Oct 19, 2020
- Last posted
- Oct 19, 2020
- Enrollment
- 44
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of WashingtonLead sponsor
- Epizyme, Inc.Collaborator
- Swedish Cancer InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.